

**Schedule 4
(non-WTO Member)**

Notification of Importation to the Government of Canada under the Decision on the Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health (adopted by the General Council on August 30, 2003) (the “Decision”)

1. Based on its present evaluation of its public health needs [country] expects to import [quantity] of [pharmaceutical product(s)].
2. [Country] is facing [details of national emergency or other circumstances of extreme urgency]
3. There is [are] no patent(s) on [pharmaceutical product(s)] in [country].

OR

[country] intends to issue [has issued] a licence for the use of the invention pertaining to [name of pharmaceutical product] without the consent of the patent holder(s) in accordance with provisions of Article 31 of the TRIPS Agreement and the provisions of the Decision.

4. In accordance with the statement read by the Chairperson of the WTO General Council upon the adoption of the Decision, [country] agrees that [pharmaceutical product(s)] will not be used for commercial purposes.
5. [country] undertakes to adopt the measures referred to in Article 4 of the Decision to prevent the re-exportation of any imported quantities of [pharmaceutical product(s)] in a manner that is contrary to the Decision.
6. The Ministry [of ____] has examined data on the pharmaceutical sector available to it [and has consulted with experts in the pharmaceutical sector] and on that basis has determined that, [excluding facilities owned or controlled by the patent holder(s),] there is currently insufficient [no] capacity in the pharmaceutical sector for manufacture of the product(s) in question to meet the country's needs.

Date of notification: